Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

--------------------- Weekly 900 mg or less Weekly 1200 mg or 1500 mg ------------------------------------------------------------------------- Loading Dose 900 mg or less Loading Dose 1200 mg or more ------------------------------------------------------------------------- Daily Dose 100 mg or less Daily Dose 150 mg or more -------------------------------------------------------------------------

The dose schedules in the Phase 1 trials were weekly 100-800 mg or loading dose (LD) 300-1800 mg on Day 1 followed by 50-150 mg daily for Days 2-21 every 28 days or LD 400-900 mg & daily 50-100 mg continuously.

In the Phase 2 trials, doses were LD 900 mg Day 1 & 150 mg daily for days 2-21 every 28 days; LD 900 mg and 100 mg daily continuously; 50 mg daily continuously without a LD; and 900-1500 mg weekly. LD was reduced for cycle 2+ of the 28 day regimens.

Results

145 patients with sarcoma were entered on studies prior to December 31, 2006 and were assessed for CBR. Partial responses were seen, in one patient each, with chondrosarcoma, extra-skeletal myxoid chondrosarcoma, leiomyosarcoma and a desmoid tumor.

At lower doses with 52 patients fully evaluable for CBR, the CBR was 52% with 4 partial responses and 23 stable disease at >= 4 months.

At higher doses with 30 patients fully evaluable for CBR, the CBR was 53% with 16 stable disease at >= 4 months.

Toxicities were mainly gastrointestinal and/or fatigue. The percentage of patients with grade 0 nausea (N), vomiting (V), diarrhea (D) and fatigue (F) for lower dose perifosine (76 patients) was 46, 49, 38 and 55% respectively compared to 26, 32, 20 and 58 percent for higher dose perifosine (69 patients). The proportion of patients with grade 2+ N, V, D and F was 20, 13, 15 and 21% for lower dose perifosine and 49, 35, 42 and 25% for higher dose perifosine.

    Conclusions


    - Perifosin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:11/27/2014)... Nov. 27, 2014 - New ... Research - JIN Co., Ltd. will launch JINS ... price of 500,000 yen or $5,000 (without tax /including two ... "ACADEMIC PACK" is a dedicated solution of "JINS MEME" to ... analyze deep data* generated by electrooculography and six-axis sensors without ...
(Date:11/26/2014)... 26, 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced today ... raise approximately $3.3 million at a price of $0.30 ... healthcare focused investor. Each unit consists of one common ... purchase warrant. Each whole warrant entitles the holder to ... for a period of five years from closing.  ...
(Date:11/26/2014)... Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... Chairman, Chief Executive Officer and President, will participate in ... at The New York Palace Hotel in ... 11:30 am Eastern Time (ET). To access ... call, go to the  Investor Relations  section of the ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3
... Iclaprim also achieved high eradication rates for ... Staphylococcus aureus (MRSA), REINACH, Switzerland, Oct. ... combined results from two pivotal Phase III,clinical ... Antimicrobial Agents,and Chemotherapy (ICAAC)/Infectious Diseases Society of ...
... Paratek Pharmaceuticals, Inc. today,announced positive Phase 2 data ... aminomethylcycline (AMC). The Phase 2 study compared,safety and ... PTK 0796 to,Zyvox(R) in the treatment of patients ... trial met its primary safety and,tolerability endpoint, demonstrating ...
Cached Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:11/28/2014)... 2014 Dr. Paul Vitenas, one of the ... & Glow Holiday Event for those in the area that would ... practice. Glitter & Glow will take place on December 11, 2014, ... in the heart of Houston at 4208 Richmond Ave. , ... that you will come and celebrate the season with us on ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Secura ... the few insurance marketing organizations in the country ... and asset protection marketplace. Secura Consultants is proud ... with Principal Financial Group, a leading global financial ... ownership interests. With the ownership interest comes the ...
(Date:11/28/2014)... 2014 (HealthDay News) -- Celebration can quickly turn ... Thanksgiving Day, experts say. Over the last decade, ... occurred while people were using turkey fryers, according to ... actually cared for a patient who tried to deep ... done in any circumstances," Dr. Arthur Sanford, a burn ...
(Date:11/28/2014)... Kramer HealthDay Reporter , THURSDAY, ... the kitchen, through cooking classes or at home, may make ... recent review. Cooking programs and classes for children seem ... the new research. And, although the review didn,t look at ... programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... November 28, 2014 PreDiabetes ... and treatment, helped employees learn their risk for ... blood screening at a local school in partnership ... Work initiative. , As the Presenting Sponsor ... , PreDiabetes Centers is co-hosting diabetes-prevention presentations at ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:PreDiabetes Centers Offers Workplace Diabetes Screening at Local School 2
... Study finds mortality and survival rates equal for both ... Minimally-invasive laparoscopic surgery and open surgery for colon cancer ... from 12 international studies involving over 3,300 patients. ... afraid that laparoscopy might impair survival in colorectal cancer ...
... not establish safe-limit price as guide for avoiding exposure ... you bought from a hip young street artist may be ... skin. , A new report finds that many pairs of ... stores and artists contain nickel, which can cause dermatitis on ...
... Bed & Back; Merger Sets Up Healthy ... Owned Back Retail Chain, LORTON, Va., May 16 ... home and workplace back wellness created an,ergonomic revolution, has ... Back. Healthy Back,s 18 stores and ecommerce division,claimed 2007 ...
... readings, study says , , FRIDAY, May 16 (HealthDay News) -- ... hormone secreted by the parathyroid glands may increase the risk ... , The Dutch study, published in the May issue ... by researchers that vitamin D, depression and other psychiatric illnesses ...
... Month-long Campaign to Emphasize the Importance of Oral ... National dental insurer United,Concordia Dental is celebrating ... and the British Dental Health Foundation to,promote the ... May 18,this year,s event is launching in the ...
... clinical trial has found that the experimental targeted therapy ... metastatic kidney cancer whose disease had worsened on other ... MD, an attending physician at Memorial Sloan-Kettering Cancer Center ... at the annual meeting of the American Society for ...
Cached Medicine News:Health News:Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries 2Health News:Cheaper Earrings More Likely to Contain Nickel 2Health News:Cheaper Earrings More Likely to Contain Nickel 3Health News:The Back Wars Come to a Close 2Health News:Low Vitamin D Tied to Depression in Older Adults 2Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Drug fends off kidney cancer progression 2
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
... is designed for use without ... allowing for full C-Arm access. ... stored onboard when more stability ... quickly slide into standard sockets ...
... The onboard rail clamps ... O.R. tables and stretchers. ... any need for lifting. ... a stable surface combined ...
... The powered torso and ... Orthopedic Trauma Table simultaneously lift ... independent lift mechanism raises and ... for precise positioning. A wide ...
Medicine Products: